---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-26-000059"
form_type: "8-K/A"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2026-09-03T20:39:01+00:00"
generated_at: "2026-09-03T20:42:34.203185+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MacroGenics restates pro forma to treat CDMO sale as discontinued ops; net cash $110.8M

## Summary
- CDMO sale to Bora closed 6/30/26; gross proceeds $122.5M, net cash $110.8M after $8.8M costs; up to $5M contingent.
- Pro forma continuing ops net loss: Q1'26 $41.3M vs $36.8M hist; FY25 $91.2M vs $74.6M; FY24 $68.6M vs $67.0M; FY23 $11.3M vs $9.1M.
- CDMO revenue eliminated from continuing ops: Q1'26 $14.1M, FY25 $52.6M, FY24 $13.1M, FY23 $9.8M.
- Company now focuses on R&D pipeline; CDMO results reported as discontinued operations.

## SEC filing metadata
- accession: 0001125345-26-000059
- form_type: 8-K/A
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2026-09-03T20:39:01+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/0001125345-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000059/mgnx-20260903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-26-000059
- JSON: https://secwatch.observer/filing/0001125345-26-000059.json
- Plain text: https://secwatch.observer/filing/0001125345-26-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.